These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28304229)

  • 1. Antidrug Antibodies in Patients Treated with Alirocumab.
    Roth EM; Goldberg AC; Catapano AL; Torri A; Yancopoulos GD; Stahl N; Brunet A; Lecorps G; Colhoun HM
    N Engl J Med; 2017 Apr; 376(16):1589-90. PubMed ID: 28304229
    [No Abstract]   [Full Text] [Related]  

  • 2. Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.
    Bays H; Gaudet D; Weiss R; Ruiz JL; Watts GF; Gouni-Berthold I; Robinson J; Zhao J; Hanotin C; Donahue S
    J Clin Endocrinol Metab; 2015 Aug; 100(8):3140-8. PubMed ID: 26030325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II).
    El Shahawy M; Cannon CP; Blom DJ; McKenney JM; Cariou B; Lecorps G; Pordy R; Chaudhari U; Colhoun HM
    Am J Cardiol; 2017 Sep; 120(6):931-939. PubMed ID: 28750828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab.
    White CM
    Ann Pharmacother; 2015 Dec; 49(12):1327-35. PubMed ID: 26424774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
    Kastelein JJ; Ginsberg HN; Langslet G; Hovingh GK; Ceska R; Dufour R; Blom D; Civeira F; Krempf M; Lorenzato C; Zhao J; Pordy R; Baccara-Dinet MT; Gipe DA; Geiger MJ; Farnier M
    Eur Heart J; 2015 Nov; 36(43):2996-3003. PubMed ID: 26330422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
    Okere AN; Serra C
    Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks.
    Roth EM; McKenney JM
    Future Cardiol; 2015; 11(1):27-37. PubMed ID: 25606700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis.
    Koren MJ; Roth EM; McKenney JM; Gipe D; Hanotin C; Ferrand AC; Wu R; Dufour R
    Postgrad Med; 2015 Mar; 127(2):125-32. PubMed ID: 25609019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials.
    Jones PH; Bays HE; Chaudhari U; Pordy R; Lorenzato C; Miller K; Robinson JG
    Am J Cardiol; 2016 Dec; 118(12):1805-1811. PubMed ID: 27729106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review.
    Farnier M
    Expert Rev Cardiovasc Ther; 2017 Dec; 15(12):923-932. PubMed ID: 29171769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
    Stroes E; Guyton JR; Lepor N; Civeira F; Gaudet D; Watts GF; Baccara-Dinet MT; Lecorps G; Manvelian G; Farnier M;
    J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27625344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alirocumab (Praluent) for Treatment of Hyperlipidemia.
    Turner PL; Barry KA
    Am Fam Physician; 2016 Aug; 94(4):310-1. PubMed ID: 27548598
    [No Abstract]   [Full Text] [Related]  

  • 13. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial.
    Roth EM; Taskinen MR; Ginsberg HN; Kastelein JJ; Colhoun HM; Robinson JG; Merlet L; Pordy R; Baccara-Dinet MT
    Int J Cardiol; 2014 Sep; 176(1):55-61. PubMed ID: 25037695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.
    Cannon CP; Cariou B; Blom D; McKenney JM; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM;
    Eur Heart J; 2015 May; 36(19):1186-94. PubMed ID: 25687353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of alirocumab for the treatment of hypercholesterolemia.
    Farnier M
    Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1307-23. PubMed ID: 26563849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
    Müller-Wieland D; Leiter LA; Cariou B; Letierce A; Colhoun HM; Del Prato S; Henry RR; Tinahones FJ; Aurand L; Maroni J; Ray KK; Bujas-Bobanovic M
    Cardiovasc Diabetol; 2017 May; 16(1):70. PubMed ID: 28545518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
    Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
    Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S
    Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alirocumab (Praluent) to lower LDL-Cholesterol.
    Med Lett Drugs Ther; 2015 Aug; 57(1475):113-5. PubMed ID: 26262881
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
    Robinson JG; Farnier M; Krempf M; Bergeron J; Luc G; Averna M; Stroes ES; Langslet G; Raal FJ; El Shahawy M; Koren MJ; Lepor NE; Lorenzato C; Pordy R; Chaudhari U; Kastelein JJ;
    N Engl J Med; 2015 Apr; 372(16):1489-99. PubMed ID: 25773378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.